Tempus AI Study Shows Pre-Screening Panel Exceeds 80% Sensitivity Across 12 Lung Cancer Biomarkers
Bitget2026/10/19 12:37- Tempus AI announced study results showing its AI-enabled pre-screening panel could help identify advanced non-small cell lung cancer patients needing biomarker testing.
- The analysis covered 60,459 cases across 56,969 patients through a collaboration with Pfizer.
- Results were presented at the European Society for Medical Oncology Congress 2026 in Madrid.
- The panel analyzes routine pathology images to help prioritize diagnostic testing, potentially accelerating treatment decisions while preserving limited tumor tissue.
- The panel remains in development as a tool to guide subsequent testing, not replace established molecular or immunohistochemistry tests.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Skonec Entertainment Faces Shareholder Register Access Lawsuit in Control Dispute
Near Protocol Surges 5% Despite DFINITY Founder Slamming Its Tech
Retail investors bet on AI infrastructure rebound, shares of South Korean cloud operator Elice rise above IPO price in two days
After plummeting 32% on its first trading day, South Korean cloud service provider Elice rebounded strongly for two consecutive days, surging as much as 25% and reclaiming its IPO price for the first time. Retail investors actively bottom-fished driven by the limit-up effect, while institutional investors questioned its financing resilience and execution capabilities. Whether the AI infrastructure sector is a value hotspot or a capital trap has become an intensifying point of contention in the market.
Japanese stocks closed down 2.65%
Crypto prices
More
